China Shineway Pharmaceutical Group Limited (2877.HK)
HKD 8.7
(-0.57%)
HKD 8.7
(-0.57%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 301.32 Million CNY | 3948.99% |
| 2022 | 7.44 Million CNY | -50.09% |
| 2021 | 14.91 Million CNY | -96.2% |
| 2020 | 392.13 Million CNY | -3.06% |
| 2019 | 404.53 Million CNY | 0.0% |
| 2018 | - CNY | 0.0% |
| 2017 | - CNY | 0.0% |
| 2016 | - CNY | 0.0% |
| 2015 | - CNY | -100.0% |
| 2014 | 200 Million CNY | -60.0% |
| 2013 | 500 Million CNY | 0.0% |
| 2012 | - CNY | 0.0% |
| 2011 | - CNY | 0.0% |
| 2010 | - CNY | 0.0% |
| 2009 | - CNY | 0.0% |
| 2008 | - CNY | 0.0% |
| 2007 | - CNY | 0.0% |
| 2006 | - CNY | 0.0% |
| 2005 | - CNY | 0.0% |
| 2004 | - CNY | 0.0% |
| 2003 | - CNY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 Q4 | 301.32 Million CNY | 0.0% |
| 2023 Q2 | 304.26 Million CNY | 0.0% |
| 2023 FY | 301.32 Million CNY | 3948.99% |
| 2022 FY | 7.44 Million CNY | -50.09% |
| 2022 Q2 | 11.1 Million CNY | 0.0% |
| 2022 Q4 | 7.44 Million CNY | 0.0% |
| 2021 Q2 | 18.95 Million CNY | 0.0% |
| 2021 FY | 14.91 Million CNY | -96.2% |
| 2021 Q4 | 14.91 Million CNY | 0.0% |
| 2020 FY | 392.13 Million CNY | -3.06% |
| 2020 Q4 | 392.13 Million CNY | 0.0% |
| 2020 Q2 | 613.66 Million CNY | 0.0% |
| 2019 FY | 404.53 Million CNY | 0.0% |
| 2019 Q2 | 5.58 Million CNY | 0.0% |
| 2019 Q4 | 404.53 Million CNY | 0.0% |
| 2018 Q4 | - CNY | 0.0% |
| 2018 FY | - CNY | 0.0% |
| 2018 Q2 | - CNY | 0.0% |
| 2017 Q4 | - CNY | 0.0% |
| 2017 Q2 | - CNY | 0.0% |
| 2017 FY | - CNY | 0.0% |
| 2016 FY | - CNY | 0.0% |
| 2016 Q4 | - CNY | 0.0% |
| 2016 Q2 | - CNY | 0.0% |
| 2015 FY | - CNY | -100.0% |
| 2015 Q4 | - CNY | 0.0% |
| 2015 Q2 | - CNY | 0.0% |
| 2014 Q4 | 200 Million CNY | 0.0% |
| 2014 FY | 200 Million CNY | -60.0% |
| 2014 Q2 | 700 Million CNY | 0.0% |
| 2013 Q2 | - CNY | 0.0% |
| 2013 FY | 500 Million CNY | 0.0% |
| 2013 Q4 | 500 Million CNY | 0.0% |
| 2012 Q4 | - CNY | 0.0% |
| 2012 FY | - CNY | 0.0% |
| 2012 Q2 | - CNY | 0.0% |
| 2011 Q2 | - CNY | 0.0% |
| 2011 Q4 | - CNY | 0.0% |
| 2011 FY | - CNY | 0.0% |
| 2010 Q4 | - CNY | 0.0% |
| 2010 FY | - CNY | 0.0% |
| 2010 Q2 | - CNY | 0.0% |
| 2009 FY | - CNY | 0.0% |
| 2009 Q4 | - CNY | 0.0% |
| 2008 FY | - CNY | 0.0% |
| 2007 FY | - CNY | 0.0% |
| 2006 FY | - CNY | 0.0% |
| 2005 FY | - CNY | 0.0% |
| 2004 FY | - CNY | 0.0% |
| 2003 FY | - CNY | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 6.8 Million HKD | -4324.758% |
| Grand Pharmaceutical Group Limited | 3.4 Billion HKD | 91.149% |
| Extrawell Pharmaceutical Holdings Limited | 120.41 Million HKD | -150.25% |
| Wai Yuen Tong Medicine Holdings Limited | 460.94 Million HKD | 34.629% |
| Qianhai Health Holdings Limited | 487 Thousand HKD | -61773.922% |
| Lee's Pharmaceutical Holdings Limited | 204.14 Million HKD | -47.608% |
| Essex Bio-Technology Limited | 294.02 Million HKD | -2.484% |
| Tongfang Kontafarma Holdings Limited | 333.82 Million HKD | 9.735% |
| PuraPharm Corporation Limited | 424.77 Million HKD | 29.061% |
| SSY Group Limited | 3.37 Billion HKD | 91.069% |
| JBM (Healthcare) Limited | 133.4 Million HKD | -125.87% |
| Jacobson Pharma Corporation Limited | 749.37 Million HKD | 59.79% |
| China Resources Pharmaceutical Group Limited | 85.84 Billion HKD | 99.649% |